Adriamycin activates c-jun N-terminal kinase in human leukemia cells: A relevance to apoptosis

Cancer Letters

Volumn 107, Issue 1, 1996, Pages 73-81

  Yu, Rong ^a   Shtil, Alexander A ^b   Tan, Tse Hua ^c   Roninson, Igor B ^b   Kong, Ah Ng Tony ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adriamycin; Apoptosis; c jun N terminal kinase 1; Extracellular signal regulated kinases; Leukemia

Indexed keywords

DOXORUBICIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; ONCOGENE C JUN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE; T CELL LEUKEMIA;

EID: 0030272630     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(96)04345-5     Document Type: Article

References (35)

1. [1] Gianni, L., Corden, B.J. and Myers, C.E. (1983) The biochemical basis of anthracycline toxicity and antitumor action, Rev. Biochem Toxicol., 5, 1-82.
2. [2] Tritton, T.R. (1991) Cell surface actions of adriamycin Pharmacol, Ther., 49, 293-309.
3. [3] Neidle, S. (1979) The molecular basis for the action of some DNA-binding drugs, Prog. Med. Chem., 16, 151-211.
4. [4] Tewey, K.M., Rowe, T.C., Yand, L., Halligan, B.D. and Liu, L.F. (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II, Science, 226, 466-468.
5. [5] Liu, L.F. (1989) DNA topoisomerase poisons as antitumor drugs, Annu. Rev. Biochem., 58, 351-375.
6. [6] Bachur, N.R., Gordon, S.L., Gee, M.V. and Kon, H. (1979) NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals, Proc. Natl. Acad. Sci. USA, 76, 954-957.
7. [7] Vichi, P. and Tritton, T.R. (1992) Adriamycin: protection from cell death by removal of extracellular drug, Cancer Res., 52, 4135-4138.
8. [8] Posada, J., Vichi, P. and Tritton, T.R. (1989) Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells, Cancer Res., 49, 6634-6639.
9. [9] Chaudhary, P.M. and Roninson, I.B. (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs, J. Natl. Cancer Inst., 85, 632-639.
10. [10] Tsuruo, T., Iida-Saito, H., Kawabata, H., Oh-Hara, T., Hamada, H. and Utakoji, T. (1986) Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones, Jpn. J. Cancer Res. (Gann), 77, 682-692.
11. [11] Yanovich, S., Hall, R.E. and Gewirtz, D.A. (1989) Characterization of K562 multidrug-resistant cell line, Cancer Res., 49, 4499-4503.
12. [12] Cobb, M.H. and Goldsmith, E.J. (1995) How MAP kinases are regulated, J. Biol. Chem., 270, 14843-14846.
13. [13] Davis, R.J. (1993) The mitogen-activated protein kinase signal transduction pathway, J. Biol. Chem., 268, 14553-14556.
14. [14] Coso, O.A., Chiariello, M., Yu, J.-C., Teramoto, H., Crespo, P., Xu, N., Miki, T. and Gutkind, S. (1995) The small GTP-binding proteins Racl and Cdc42 regulate the activity of the JNK/SAPK signaling pathway, Cell, 81, 1137-1146.
15. [15] Minden, A., Lin, A., Claret, F.X., Abo, A. and Karin, M. (1995) Selective activation of the JNK signaling cascade and c-jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell., 81, 1147-1157.
16. [16] Karin, M.J. (1995) The regulation of AP-1 activity by mitogen-activated protein kinases, J. Biol. Chem., 270, 16483-16486.
17. [17] van Dam, H., Wilhelm, D., Herr, I., Steffen, A., Herrlich, P. and Angel, P. (1995) ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents, EMBO J., 14, 1798-1811.
18. [18] Cavigelli, M., Dolfi, F., Claret, F.-X. and Karin, M. (1995) Induction of c-fos expression through JNK-mediated TCF/ Elk-1 phosphorylatlon, EMBO J., 14, 5957-5964.
19. [19] Liang, G., Wolfgang, C.D., Chen, B.P.C., Chen, T.-H. and Hai, T. (1996) ATF3 gene: genomic organization, promoter and regulation, J. Biol. Chem., 271, 1695-1701.
20. [20] Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J. and Greenberg, M.E. (1995) Opposite effects of ERK and JNK-p38 kinases on apoptosis, Science, 270, 1326-1331.
21. [21] Derijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M. and Davis, R.J. (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain, Cell, 76, 1025-1037.
22. [22] Verheij, M., Bose, R., Lin, X.H., Yao, B., Jarvis, W.D., Grant, S., Birrer, M.J., Szabo, E., Zon, L.I., Kyriakis, J.M., Haimovitz-Friedman, A., Fuks, Z. and Kolesnik, R.N. (1996) Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis, Nature, 380, 75-79.
23. [23] Chen, Y.R., Meyer, C.F. and Tan, T.H. (1996) Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in γ-radiation-induced apoptosis, J. Biol. Chem., 271, 631-634.
24. [24] Yan, M., Dai, T., Deak, J.C., Kyriakis, J.M., Zon, L.I., Woodgett, J.R. and Templeton, D.J. (1994) Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1, Nature, 372, 798-800.
25. [25] Kyriakis, J.M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E.A., Ahmad, M.F., Avruch, J. and Woodgett, J.R. (1994) The stress-activated protein kinase subfamily of c-Jun kinases, Nature, 369, 156-160.
26. [26] Cano, E. and Mahadevan, L.C. (1995) Parallel signal processing among mammalian MAPKs, Trends Biochem. Sci., 20, 117-122.
27. [27] Salmeron, A., Ahmad, T.B., Carlile, G.W., Pappin, D., Narsimhan, R.P. and Ley, S.C. (1996) Activation of MEK-1 and SEK-1 by Tpl-2 protooncoprotein, a novel MAP kinase kinase kinase, EMBO J., 15, 817-826.
28. [28] Saleem, A., Datta, R., Yuan, Z.M., Kharbanda, S. and Kufe, D. (1995) Involvement of stress-activated protein kinase in the cellular response to 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents, Cell Growth Differ., 6, 1651-1658.
29. [29] Hibi, M., Lin, A., Minden, A. and Karin, M. (1993) Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain, Genes Dev., 7, 2135-2148.
30. [30] Hattori, K., Angel, P., Le Beau, M.M. and Karin, M. (1988) Structure and chromosomal localization of the functional intronless human JUN protooncogene, Proc. Natl. Acad. Sci. USA, 85, 9148-9152.
31. [31] Noonan, K.E., Beek, C., Holzmayer. T.A., Chin, J.E., Wunder, J.S., Andrulis, I.L., Gazdar, A.F., Willman, C.L., Griffith, B., von Hoff, D.D. and Roninson, I.B. (1990) Quantitative analysis of MDRI (multidrug resistance) gene expression in human tumors by polymerase chain reaction, Proc. Natl. Acad. Sci. USA, 87, 7160-7164.
32. 2: role in cell survival following oxidant injury, J. Biol. Chem, 271, 4138-4142.
33. [33] Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z. and Kolesnik, R. (1995) Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals, Cell, 82, 405-414.
34. [34] Hollander Jr., M.C. and Fornace, A.J. (1989) Induction of fos RNA by DNA-damaging agents, Cancer Res., 49, 1687-1692.
35. [35] Chen, B.P.C., Wolfgang, C.D. and Hai, T. (1996) Analysis of ATF3, a transcriptional factor induced by physiological stresses and modulated by gadd153/Chop10, Mol. Cell. Biol., 16, 1157-1168.